Since it is associated with increased patient and graft survival rates, it has become the treatment of choice for high risk cases such as when the donor is CMV IgG positive but the recipient is CMV IgG Negative.
A pesar de los avances en la inmunosupresión, el rechazo del injerto hepático continúa siendo una causa importante de morbilidad y de pérdida del injerto en algunos pacientes 45.